MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
IPO Year: 2004
Exchange: NASDAQ
Website: mannkindcorp.com
Recent Analyst Ratings for MannKind Corporation
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/10/2025 | $11.00 | Outperform | Wedbush |
12/20/2024 | $9.00 | Overweight | Wells Fargo |
12/19/2024 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
9/9/2024 | $7.00 → $8.00 | Outperform | Leerink Partners |
6/13/2024 | $8.00 | Buy | Rodman & Renshaw |
10/10/2023 | $10.00 | Outperform | Wedbush |
2/28/2022 | $6.50 → $6.00 | Buy | HC Wainwright & Co. |
MannKind Corporation Press Releases
Fastest customizable press release news feed in the world
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio
MannKind to Present at Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at three investor conferences during the first quarter of 2025. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual)Tuesday, February 11, 11:20 a.m. ET Leerink Partners 2025 Global Healthcare Conference
MannKind Expands Executive Leadership Team
Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025. Mr. Marasco is a member of MannKind's executive leadership team and reports to Michael Castagna, PharmD, Chief Executive Officer. "Dominic is an innovative leader recogniz
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced today that it has entered into separate, privately negotiated exchange agreements with certain holders (the "Holders") of its 2.50% Convertible Senior Notes due 2026 (the "Notes"). Under the terms of the exchange agreements, the Holders agreed to exchange an aggregate principal amount of approximately $193.7 million of Notes held by them in exchange for an aggregate of 26,749,559 shares of the Company's common stock ("Shares"). In addition, pursuant to the exchan
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship product for Cipla Ltd. by end of 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, and Cipla Ltd. announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in the United
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended September 30, 2024. "Our business demonstrated double-digit revenue growth compared to last year, led by Tyvaso DPI revenues,"
MannKind to Present at 2024 UBS Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during a fireside chat at the 2024 UBS Healthcare Conference in Rancho Palos Verdes, Calif. The fireside chat will take place on Tuesday, November 12, at 10:15 a.m. Pacific Time. A link to the live audio webcast of the session will be available on MannKind Corporation's website at
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idio
MannKind Corporation Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wedbush initiated coverage on Mannkind with a new price target
Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00
Wells Fargo initiated coverage on Mannkind with a new price target
Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00
Mannkind upgraded by RBC Capital Mkts with a new price target
RBC Capital Mkts upgraded Mannkind from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Leerink Partners resumed coverage on Mannkind with a new price target
Leerink Partners resumed coverage of Mannkind with a rating of Outperform and set a new price target of $8.00 from $7.00 previously
Rodman & Renshaw initiated coverage on Mannkind with a new price target
Rodman & Renshaw initiated coverage of Mannkind with a rating of Buy and set a new price target of $8.00
Wedbush initiated coverage on Mannkind with a new price target
Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage on MannKind with a new price target
HC Wainwright & Co. reiterated coverage of MannKind with a rating of Buy and set a new price target of $6.00 from $6.50 previously
RBC Capital initiated coverage on MannKind with a new price target
RBC Capital initiated coverage of MannKind with a rating of Sector Perform and set a new price target of $5.00
SVB Leerink reiterated coverage on MannKind with a new price target
SVB Leerink reiterated coverage of MannKind with a rating of Outperform and set a new price target of $5.00 from $3.00 previously
SVB Leerink reiterated coverage on MannKind with a new price target
SVB Leerink reiterated coverage of MannKind with a rating of Outperform and set a new price target of $5.00 from $3.00 previously
MannKind Corporation Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Pres, Endocrine Business Unit Marasco Dominic was granted 252,000 shares (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
SEC Form 3 filed by new insider Marasco Dominic
3 - MANNKIND CORP (0000899460) (Issuer)
Director Binder Steven B. exercised 67,536 shares at a strike of $1.47 and sold $465,323 worth of shares (67,536 units at $6.89) (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
Director Binder Steven B. exercised 67,539 shares at a strike of $1.47 and sold $456,564 worth of shares (67,539 units at $6.76) (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
Chief People & Workpl Officer Tross Stuart A sold $403,700 worth of shares (55,000 units at $7.34), decreasing direct ownership by 5% to 967,191 units (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
EVP Technical Operations Singh Sanjay R covered exercise/tax liability with 17,071 shares, decreasing direct ownership by 4% to 385,416 units (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
Chief People & Workpl Officer Tross Stuart A sold $156,500 worth of shares (25,000 units at $6.26), decreasing direct ownership by 2% to 1,022,191 units (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
Chief People & Workpl Officer Tross Stuart A sold $506,050 worth of shares (80,000 units at $6.33), decreasing direct ownership by 7% to 1,047,191 units (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
EVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 22,489 shares and sold $32,985 worth of shares (5,553 units at $5.94), decreasing direct ownership by 3% to 829,843 units (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
Chief Executive Officer Castagna Michael covered exercise/tax liability with 56,085 shares, gifted 32,894 shares and sold $536,168 worth of shares (85,106 units at $6.30), decreasing direct ownership by 7% to 2,294,836 units (SEC Form 4)
4 - MANNKIND CORP (0000899460) (Issuer)
MannKind Corporation SEC Filings
SEC Form S-3ASR filed by MannKind Corporation
S-3ASR - MANNKIND CORP (0000899460) (Filer)
SEC Form 10-K filed by MannKind Corporation
10-K - MANNKIND CORP (0000899460) (Filer)
MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MANNKIND CORP (0000899460) (Filer)
MannKind Corporation filed SEC Form 8-K: Leadership Update
8-K - MANNKIND CORP (0000899460) (Filer)
MannKind Corporation filed SEC Form 8-K: Other Events
8-K - MANNKIND CORP (0000899460) (Filer)
SEC Form 10-Q filed by MannKind Corporation
10-Q - MANNKIND CORP (0000899460) (Filer)
MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MANNKIND CORP (0000899460) (Filer)
SEC Form 8-K filed by MannKind Corporation
8-K - MANNKIND CORP (0000899460) (Filer)
SEC Form 10-Q filed by MannKind Corporation
10-Q - MANNKIND CORP (0000899460) (Filer)
MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MANNKIND CORP (0000899460) (Filer)
MannKind Corporation Leadership Updates
Live Leadership Updates
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.
MannKind Corporation Financials
Live finance-specific insights
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended September 30, 2024. "Our business demonstrated double-digit revenue growth compared to last year, led by Tyvaso DPI revenues,"
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung programs to human studies MNKD-101 Phase 3 clinical trial activities initiatedMNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended June 30, 2024. "We achieved our ninth consecutive quarter of revenue growth and are approaching an annual revenue run rate of over $275 million based on the first half of 2024," said M
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website a
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
1Q 2024 Total revenues of $66M; +63% vs. 1Q 20231Q 2024 Net income of $11M; Non-GAAP net income of $15M$304M of cash and cash equivalents and investments at March 31, 2024In early April, repaid Midcap senior-secured debt and Mann Group convertible debt totaling approximately $37M FDA Fast Track designation and IND clearance received for MNKD-101 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2024. "We achieved our eighth consecutive quarter of revenue growth putting us on a run rate of over $250 million in revenue for 2024," said Michael Castagna, PharmD, Chi
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About MannKind CorporationMannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to ad
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
2023 Total revenues of $199M; +99% vs. 20224Q 2023 Total revenues of $58M; +62% vs. 20224Q 2023 Net income of $1M; Non-GAAP net income of $7M$302M of cash and cash equivalents and investments at December 31, 2023 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and full year ended December 31, 2023. "We doubled our total revenues to nearly $200 million in 2023 and ended the year with a robust fourth quarter total revenue of $58 million," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "With our strong year-end cash position of over
MannKind Corporation Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G/A filed by MannKind Corporation (Amendment)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SEC Form SC 13G/A filed by MannKind Corporation (Amendment)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SEC Form SC 13G/A filed by MannKind Corporation (Amendment)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SEC Form SC 13G/A filed by MannKind Corporation (Amendment)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SEC Form SC 13G filed by MannKind Corporation
SC 13G - MANNKIND CORP (0000899460) (Subject)
SEC Form SC 13G/A filed by MannKind Corporation (Amendment)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SEC Form SC 13G filed
SC 13G - MANNKIND CORP (0000899460) (Subject)